Chromium picolinate intake and risk of type 2 diabetes: an evidence-based review by the United States Food and Drug Administration.
The labeling of both health claims that meet significant scientific agreement (SSA) and qualified health claims on conventional foods and dietary supplements requires pre-market approval by the US Food and Drug Administration (FDA). Approval by the FDA involves, in part, a thorough review of the scientific evidence to support an SSA or a qualified health claim. This article discusses FDA's evidence-based review of the scientific evidence on the role of chromium picolinate supplements in reducing the risk of type 2 diabetes. Based on this evidence-based review, FDA issued a letter of enforcement discretion for one qualified health claim on chromium picolinate and risk of insulin resistance, a surrogate endpoint for type 2 diabetes. The agency concluded that the relationship between chromium picolinate intake and insulin resistance is highly uncertain.
Trumbo
Paula R
PR
Division of Nutrition Programs and Labeling, US Food and Drug Administration, College Park, Maryland, USA. Paula.Trumbo@FDA.gov
Ellwood
Kathleen C
KC
D001786:Blood Glucose / Q000187:drug effects; D003924:Diabetes Mellitus, Type 2 / Q000453:epidemiology* / Q000517:prevention & control; D019587:Dietary Supplements; D019317:Evidence-Based Medicine; D005515:Food Labeling; D006801:Humans; D007333:Insulin Resistance; D010848:Picolinic Acids / Q000627:therapeutic use*; D012307:Risk Factors; D014481:United States; D014486:United States Food and Drug Administration
D001786:Blood Glucose; D010848:Picolinic Acids; C030614:picolinic acid